Article
An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cancer medicine - 1 Nov 2020
Cowey Charles L, Boyd Marley, Aguilar Kathleen M, Beeks April, Krepler Clemens, Scherrer Emilie
Abstract excerpt
INTRODUCTION: Anti-PD-1 monotherapies (aPD-1) and BRAF/MEK inhibitors (BRAF/MEKi) changed the BRAF-mutant advanced melanoma treatment landscape. This study aimed to improve the understanding of real-world treatment patterns and optimal treatment sequence. METHODS: This was a retrospective study of BRAF-mutant advanced melanoma patients who initiated 1L aPD-1 or BRAF/MEKi in the US Oncology Network between 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.